Low molecular weight heparins: the optimal treatment for venous thromboembolism
SUMMARY Venous thromboembolism (VTE) is a common vascular complication that requires immediate as well as long-term treatment. Recent trials evaluated the efficacy and safety of LMWH therapy as an alternative to vitamin K antagonists in long-term VTE secondary prophylaxis for all patients and in spe...
Gespeichert in:
| Veröffentlicht in: | Current medical research and opinion 2004-07, Vol.20 (7), p.1001-1005 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1005 |
|---|---|
| container_issue | 7 |
| container_start_page | 1001 |
| container_title | Current medical research and opinion |
| container_volume | 20 |
| creator | Daskalopoulos, Marios E. Daskalopoulou, Stella S. Liapis, Christos D. |
| description | SUMMARY
Venous thromboembolism (VTE) is a common vascular complication that requires immediate as well as long-term treatment.
Recent trials evaluated the efficacy and safety of LMWH therapy as an alternative to vitamin K antagonists in long-term VTE secondary prophylaxis for all patients and in specific subgroups.
In this brief overview, we consider the potential advantages of treatment with LMWH in patients with VTE. |
| doi_str_mv | 10.1185/030079904125004024 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_66726350</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>677162501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-8f2c810f4e4bb94e0d6c63b85f70608b76ee4d1e56146a1bcf3a1f0ebc2d22333</originalsourceid><addsrcrecordid>eNp9kE1LHTEUhkOp1Kv2D3RRhi7cjc13ZqQuRKoWLrjRdchkTjojmcltkvHiv2_kXpBacHE4m-c9Hw9CXwg-I6QR3zHDWLUt5oQKjDmm_ANaEa5YzRulPqLVC1AXQhyio5QeMSa0adtP6JAIKgXlfIXu1mFbTcGDXbyJ1RbG30OuBtiYOM7pvMoDVGGTx8n4KkcweYI5Vy7E6gnmsKQCxDB1AUr5MU0n6MAZn-Dzvh-jh-uf91e39fru5tfV5bq2XKlcN47ahmDHgXddywH30krWNcIpLHHTKQnAewJCEi4N6axjhjgMnaU9pYyxY3S6m7uJ4c8CKetpTBa8NzOUs7SUikomcAG_vQEfwxLncpumxZ4UTLYFojvIxpBSBKc3sbwcnzXB-sW1_t91CX3dT166CfrXyF5uAS52wDgXYZPZhuh7nc2zD9FFM9sxafbugh__5AcwPg_WRHj94Z34X6Wzn24</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>207965369</pqid></control><display><type>article</type><title>Low molecular weight heparins: the optimal treatment for venous thromboembolism</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Daskalopoulos, Marios E. ; Daskalopoulou, Stella S. ; Liapis, Christos D.</creator><creatorcontrib>Daskalopoulos, Marios E. ; Daskalopoulou, Stella S. ; Liapis, Christos D.</creatorcontrib><description>SUMMARY
Venous thromboembolism (VTE) is a common vascular complication that requires immediate as well as long-term treatment.
Recent trials evaluated the efficacy and safety of LMWH therapy as an alternative to vitamin K antagonists in long-term VTE secondary prophylaxis for all patients and in specific subgroups.
In this brief overview, we consider the potential advantages of treatment with LMWH in patients with VTE.</description><identifier>ISSN: 0300-7995</identifier><identifier>EISSN: 1473-4877</identifier><identifier>DOI: 10.1185/030079904125004024</identifier><identifier>PMID: 15265244</identifier><identifier>CODEN: CMROCX</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Heparin, Low-Molecular-Weight - economics ; Heparin, Low-Molecular-Weight - therapeutic use ; Humans ; Key words: Deep venous thrombosis ; Low molecular weight heparin ; Oral anticoagulants ; Pulmonary Embolism - drug therapy ; Thromboembolism - drug therapy ; Tinzaparin ; Venous thromboembolism ; Venous Thrombosis - drug therapy</subject><ispartof>Current medical research and opinion, 2004-07, Vol.20 (7), p.1001-1005</ispartof><rights>2004 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2004</rights><rights>Copyright Librapharm Jul 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-8f2c810f4e4bb94e0d6c63b85f70608b76ee4d1e56146a1bcf3a1f0ebc2d22333</citedby><cites>FETCH-LOGICAL-c477t-8f2c810f4e4bb94e0d6c63b85f70608b76ee4d1e56146a1bcf3a1f0ebc2d22333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1185/030079904125004024$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1185/030079904125004024$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,59645,59751,60434,60540,61219,61254,61400,61435</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15265244$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Daskalopoulos, Marios E.</creatorcontrib><creatorcontrib>Daskalopoulou, Stella S.</creatorcontrib><creatorcontrib>Liapis, Christos D.</creatorcontrib><title>Low molecular weight heparins: the optimal treatment for venous thromboembolism</title><title>Current medical research and opinion</title><addtitle>Curr Med Res Opin</addtitle><description>SUMMARY
Venous thromboembolism (VTE) is a common vascular complication that requires immediate as well as long-term treatment.
Recent trials evaluated the efficacy and safety of LMWH therapy as an alternative to vitamin K antagonists in long-term VTE secondary prophylaxis for all patients and in specific subgroups.
In this brief overview, we consider the potential advantages of treatment with LMWH in patients with VTE.</description><subject>Heparin, Low-Molecular-Weight - economics</subject><subject>Heparin, Low-Molecular-Weight - therapeutic use</subject><subject>Humans</subject><subject>Key words: Deep venous thrombosis</subject><subject>Low molecular weight heparin</subject><subject>Oral anticoagulants</subject><subject>Pulmonary Embolism - drug therapy</subject><subject>Thromboembolism - drug therapy</subject><subject>Tinzaparin</subject><subject>Venous thromboembolism</subject><subject>Venous Thrombosis - drug therapy</subject><issn>0300-7995</issn><issn>1473-4877</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kE1LHTEUhkOp1Kv2D3RRhi7cjc13ZqQuRKoWLrjRdchkTjojmcltkvHiv2_kXpBacHE4m-c9Hw9CXwg-I6QR3zHDWLUt5oQKjDmm_ANaEa5YzRulPqLVC1AXQhyio5QeMSa0adtP6JAIKgXlfIXu1mFbTcGDXbyJ1RbG30OuBtiYOM7pvMoDVGGTx8n4KkcweYI5Vy7E6gnmsKQCxDB1AUr5MU0n6MAZn-Dzvh-jh-uf91e39fru5tfV5bq2XKlcN47ahmDHgXddywH30krWNcIpLHHTKQnAewJCEi4N6axjhjgMnaU9pYyxY3S6m7uJ4c8CKetpTBa8NzOUs7SUikomcAG_vQEfwxLncpumxZ4UTLYFojvIxpBSBKc3sbwcnzXB-sW1_t91CX3dT166CfrXyF5uAS52wDgXYZPZhuh7nc2zD9FFM9sxafbugh__5AcwPg_WRHj94Z34X6Wzn24</recordid><startdate>200407</startdate><enddate>200407</enddate><creator>Daskalopoulos, Marios E.</creator><creator>Daskalopoulou, Stella S.</creator><creator>Liapis, Christos D.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><general>Informa Healthcare</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>200407</creationdate><title>Low molecular weight heparins: the optimal treatment for venous thromboembolism</title><author>Daskalopoulos, Marios E. ; Daskalopoulou, Stella S. ; Liapis, Christos D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-8f2c810f4e4bb94e0d6c63b85f70608b76ee4d1e56146a1bcf3a1f0ebc2d22333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Heparin, Low-Molecular-Weight - economics</topic><topic>Heparin, Low-Molecular-Weight - therapeutic use</topic><topic>Humans</topic><topic>Key words: Deep venous thrombosis</topic><topic>Low molecular weight heparin</topic><topic>Oral anticoagulants</topic><topic>Pulmonary Embolism - drug therapy</topic><topic>Thromboembolism - drug therapy</topic><topic>Tinzaparin</topic><topic>Venous thromboembolism</topic><topic>Venous Thrombosis - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Daskalopoulos, Marios E.</creatorcontrib><creatorcontrib>Daskalopoulou, Stella S.</creatorcontrib><creatorcontrib>Liapis, Christos D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Current medical research and opinion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Daskalopoulos, Marios E.</au><au>Daskalopoulou, Stella S.</au><au>Liapis, Christos D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low molecular weight heparins: the optimal treatment for venous thromboembolism</atitle><jtitle>Current medical research and opinion</jtitle><addtitle>Curr Med Res Opin</addtitle><date>2004-07</date><risdate>2004</risdate><volume>20</volume><issue>7</issue><spage>1001</spage><epage>1005</epage><pages>1001-1005</pages><issn>0300-7995</issn><eissn>1473-4877</eissn><coden>CMROCX</coden><abstract>SUMMARY
Venous thromboembolism (VTE) is a common vascular complication that requires immediate as well as long-term treatment.
Recent trials evaluated the efficacy and safety of LMWH therapy as an alternative to vitamin K antagonists in long-term VTE secondary prophylaxis for all patients and in specific subgroups.
In this brief overview, we consider the potential advantages of treatment with LMWH in patients with VTE.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>15265244</pmid><doi>10.1185/030079904125004024</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-7995 |
| ispartof | Current medical research and opinion, 2004-07, Vol.20 (7), p.1001-1005 |
| issn | 0300-7995 1473-4877 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66726350 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Heparin, Low-Molecular-Weight - economics Heparin, Low-Molecular-Weight - therapeutic use Humans Key words: Deep venous thrombosis Low molecular weight heparin Oral anticoagulants Pulmonary Embolism - drug therapy Thromboembolism - drug therapy Tinzaparin Venous thromboembolism Venous Thrombosis - drug therapy |
| title | Low molecular weight heparins: the optimal treatment for venous thromboembolism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T03%3A10%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20molecular%20weight%20heparins:%20the%20optimal%20treatment%20for%20venous%20thromboembolism&rft.jtitle=Current%20medical%20research%20and%20opinion&rft.au=Daskalopoulos,%20Marios%20E.&rft.date=2004-07&rft.volume=20&rft.issue=7&rft.spage=1001&rft.epage=1005&rft.pages=1001-1005&rft.issn=0300-7995&rft.eissn=1473-4877&rft.coden=CMROCX&rft_id=info:doi/10.1185/030079904125004024&rft_dat=%3Cproquest_pubme%3E677162501%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=207965369&rft_id=info:pmid/15265244&rfr_iscdi=true |